Schall, Brown & Schwartz LLP reminds Erasca, Inc. investors of a pending securities fraud class action, with a lead plaintiff deadline of August 10, 2026. The lawsuit covers shareholders who purchased ERAS shares between January 14, 2025 and April 26, 2026, alleging the company made false and misleading statements about its preclinical data for ERAS-0015. The complaint claims Erasca's data relied on an improper comparison to Revolution Medicines, Inc., exposing it to patent violation risks and lacking a basis for its optimistic projections. When the market learned the truth, investors suffered damages.
Erasca IncSecurities fraud lawsuit alleging false statements about ERAS-0015 data
Revolution Medicines Inc